

Statement



Request for Amendment to Connecticut House Bill 5130

March 1, 2010

Position: PhRMA respectfully asks for drugs and biologics and their corresponding packaging to be exempted from H 5130. PhRMA respects the state's desire to review chemicals used in children's products, but this review and the resulting prohibition of manufacturing and selling products with chemicals of concern is not necessary for drugs and biologics. This is because the Food and Drug Administration already scrutinizes and approves chemicals used in drugs and biologics and packaging used for these products for safety.

The Pharmaceutical Research and Manufacturers of America (PhRMA) commends Connecticut's intent to increase protections for the safety and general welfare of Connecticut's children. We respectfully ask for an amendment to H 5130 to exempt drugs, biologics and the packaging of drugs and biologics from this bill.

The United States Food and Drug Administration (FDA) already severely scrutinizes all materials used as ingredients in or in the production of medicines, or the packaging of medicines, whether intended for use by humans or animals, for both their safety and effectiveness. All prescription drug products and biologics, including the packaging, for children have been reviewed by the FDA.

Because FDA governs prescription medicines, biologics, and packaging and requires pharmaceutical companies to provide much information about the safety and effectiveness of drugs, biologics, and packaging (e.g., FDA requires studies to ensure that drug and biologic packaging does not affect the medicine and is safe for use), we respectfully request the exemption of drugs, biologics and the packaging of drugs and biologics from this bill.